BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ); it reduces substrate phosphorylation, leading to morphological changes, inhibition of motility, and decreased invasiveness in cancer cells.